Under

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

Rivaroxaban, a New Oral, Once-Daily Direct Factor Xa Inhibitor,Shows a Significant Reduction in Deep Vein Thrombosis and PulmonaryEmbolism Compared with Enoxaparin with Similarly Low BleedingRates GENEVA, July 8, 2007 - Late-breaking Phase III clinical trialdata presented today at the XXI International Society on Thrombosisand Haemostasis (ISTH) Congress demonstrate that once-daily...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

GENEVA--(BUSINESS WIRE)--Jul 8, 2007 - Late-breaking Phase IIIclinical trial data presented today at the XXI InternationalSociety on Thrombosis and Haemostasis (ISTH) Congress demonstratethat once-daily rivaroxaban achieved superior efficacy in theprevention of venous thromboembolism (VTE) in patients undergoingknee replacement surgery in a head-to-head comparison withenoxaparin, the curren...

Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia

Data Highlights the Impact of Insomnia on Healthcare System andWorker Productivity SAN DIEGO, June 12, 2007 /PRNewswire-FirstCall/ -- NeurocrineBiosciences, Inc. announced today that results from severalresearch studies on the impact of chronic primary and transientinsomnia were presented this week at the Associated ProfessionalSleep Societies (APSS) Annual Meeting. APSS highlights show t...

DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp

CUPERTINO, Calif., May 17, 2007 /PRNewswire-FirstCall/ -- DURECTCorporation announced today that Voyager Pharmaceutical hasprovided its shareholders with an update on its truncated Phase 3clinical trial for Memryte, an investigational drug for thetreatment of Alzheimer's disease. Voyager has informed itsshareholders that they have observed positive outcome trends amongwomen, but no posit...

Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action

EXTON, Pa.--(BUSINESS WIRE)--Apr 19, 2007 - Othera Pharmaceuticals,Inc. today announced that Dr. Shaker Mousa, Professor ofPharmacology and Executive Vice President and Chairman of thePharmaceutical Research Institute at Albany College of Pharmacy,will present new preclinical data detailing the observedantithrombotic effect of Othera's lead compound, OT-551, andrelated Othera compounds. Thi...

Cequent Pharmaceuticals Founder to Present tkRNAi Technology at the American Association of Cancer Research Annual Meeting in Los Angeles

CAMBRIDGE, Mass., April 13, 2007 /PRNewswire/ -- CequentPharmaceuticals, a pioneer in the development of novel products todeliver RNAi-based treatments to prevent and treat human disease,announced that its founder, Chiang Li, MD, will present ascientific poster on Cequent's proprietary TransKingdom RNAinterference (tkRNAi(TM)) technology at the 2007 annual meeting ofthe American Associat...

Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical Data for INO-1001 at ACC Demonstrating PARP Inhibition and Anti-inflammatory Activity in Plasma of Patients Undergoing Primary Percutaneous Coronary Intervention

BEVERLY, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - InotekPharmaceuticals Corporation announced today the presentation ofpositive Phase 2 clinical data demonstrating the safety of INO-1001as well as the potential for INO-1001 as a preventative agent forcardiac reperfusion injury. The study was conducted in subjectswith acute ST-elevated myocardial infarction (STEMI) undergoingprimary percutaneo...

MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study of Aquavan Injection in Patients Undergoing Bronchoscopy

MINNEAPOLIS--(BUSINESS WIRE)--Mar 20, 2007 - MGI PHARMA, INC.(NASDAQ: MOGN), a biopharmaceutical company focused in oncology andacute care, today announced that a randomized, double-blind,multi-center, pivotal phase 3 trial of Aquavan(R) (fospropofoldisodium) Injection for sedation of patients undergoingbronchoscopy successfully met its primary endpoint of sedationsuccess as well as all sec...

Use of Sequenom's MassARRAY System Leads to Significant Scientific Advances in Understanding Cancer, Diabetes and Drug-Resistant Malaria

SAN DIEGO--(BUSINESS WIRE)--Mar 14, 2007 - Sequenom, Inc. (NASDAQ:SQNM) today announced that its MassARRAY(R) technology andiPLEX(TM) assay were used by leading scientists from internationalresearch institutions and, in independent studies, significantlyadvanced the understanding of cancer, diabetes and drug-resistantmalaria. Results from several of these studies were published inhighly rec...

Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 8, 2007 - Magen BioSciences,Inc., a specialty dermatology company, today announced thepublication of a paper in the March 9, 2007 issue of the journalCell by its co-founder and board member, David E. Fisher, M.D.,Ph.D., that identifies two new functions for an important protein,p53, in the pigmentation of skin. Fisher's study shows that inaddition to i...